416 related articles for article (PubMed ID: 30105918)
1. Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell.
Dar MJ; Din FU; Khan GM
Drug Deliv; 2018 Nov; 25(1):1595-1606. PubMed ID: 30105918
[TBL] [Abstract][Full Text] [Related]
2. Nano-elastic liposomes as multidrug carrier of sodium stibogluconate and ketoconazole: A potential new approach for the topical treatment of cutaneous Leishmaniasis.
Dar MJ; Khalid S; Varikuti S; Satoskar AR; Khan GM
Eur J Pharm Sci; 2020 Mar; 145():105256. PubMed ID: 32032778
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of novel miltefosine-polyphenol co-loaded second generation nano-transfersomes for the topical treatment of cutaneous leishmaniasis.
Dar MJ; McElroy CA; Khan MI; Satoskar AR; Khan GM
Expert Opin Drug Deliv; 2020 Jan; 17(1):97-110. PubMed ID: 31786952
[No Abstract] [Full Text] [Related]
4. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
Sinha R; Roychoudhury J; Palit P; Ali N
Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
[TBL] [Abstract][Full Text] [Related]
5. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.
Carter KC; Baillie AJ; Mullen AB
Clin Diagn Lab Immunol; 1999 Jan; 6(1):61-5. PubMed ID: 9874665
[TBL] [Abstract][Full Text] [Related]
6. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study.
El-Sayed M; Anwar AE
J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):335-40. PubMed ID: 19744259
[TBL] [Abstract][Full Text] [Related]
7. Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.
Roychoudhury J; Sinha R; Ali N
PLoS One; 2011 Mar; 6(3):e17376. PubMed ID: 21423750
[TBL] [Abstract][Full Text] [Related]
8. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
[TBL] [Abstract][Full Text] [Related]
9. Macrophage targeting with the novel carbopol-based miltefosine-loaded transfersomal gel for the treatment of cutaneous leishmaniasis:
Batool S; Zahid F; Ud-Din F; Naz SS; Dar MJ; Khan MW; Zeb A; Khan GM
Drug Dev Ind Pharm; 2021 Mar; 47(3):440-453. PubMed ID: 33615936
[TBL] [Abstract][Full Text] [Related]
10. Nitazoxanide and quercetin co-loaded nanotransfersomal gel for topical treatment of cutaneous leishmaniasis with macrophage targeting and enhanced anti-leishmanial effect.
Bashir S; Shabbir K; Din FU; Khan SU; Ali Z; Khan BA; Kim DW; Khan GM
Heliyon; 2023 Nov; 9(11):e21939. PubMed ID: 38027656
[TBL] [Abstract][Full Text] [Related]
11. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
[TBL] [Abstract][Full Text] [Related]
12. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.
Carter KC; Mullen AB; Sundar S; Kenney RT
Antimicrob Agents Chemother; 2001 Dec; 45(12):3555-9. PubMed ID: 11709339
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of short-duration (twice weekly) intralesional sodium stibogluconate in treatment of cutaneous Leishmaniasis in India.
Bumb RA; Mehta RD; Ghiya BC; Jakhar R; Prasad N; Soni P; Lezama-Davila C; Satoskar AR
Br J Dermatol; 2010 Oct; 163(4):854-8. PubMed ID: 20500797
[TBL] [Abstract][Full Text] [Related]
14. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations.
Banduwardene R; Mullen AB; Carter KC
Int J Immunopharmacol; 1997 Apr; 19(4):195-203. PubMed ID: 9373770
[TBL] [Abstract][Full Text] [Related]
15. Antileishmanial Agents Co-loaded in Transfersomes with Enhanced Macrophage Uptake and Reduced Toxicity.
Zahid F; Batool S; Ud-Din F; Ali Z; Nabi M; Khan S; Salman O; Khan GM
AAPS PharmSciTech; 2022 Aug; 23(6):226. PubMed ID: 35970966
[TBL] [Abstract][Full Text] [Related]
16. Fractional ablative carbon dioxide laser followed by topical sodium stibogluconate application: A treatment option for pediatric cutaneous leishmaniasis.
Hilerowicz Y; Koren A; Mashiah J; Katz O; Sprecher E; Artzi O
Pediatr Dermatol; 2018 May; 35(3):366-369. PubMed ID: 29574997
[TBL] [Abstract][Full Text] [Related]
17. Topical delivery of tetrahydrocurcumin lipid nanoparticles effectively inhibits skin inflammation: in vitro and in vivo study.
Kakkar V; Kaur IP; Kaur AP; Saini K; Singh KK
Drug Dev Ind Pharm; 2018 Oct; 44(10):1701-1712. PubMed ID: 29938544
[TBL] [Abstract][Full Text] [Related]
18. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.
Mullen AB; Baillie AJ; Carter KC
Antimicrob Agents Chemother; 1998 Oct; 42(10):2722-5. PubMed ID: 9756784
[TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis.
Solomon M; Baum S; Barzilai A; Scope A; Trau H; Schwartz E
J Am Acad Dermatol; 2007 Apr; 56(4):612-6. PubMed ID: 17276541
[TBL] [Abstract][Full Text] [Related]
20. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
